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Abstract _ The effects of dextrometorphan and its metabolite dextrorphan on nicotine-induced antinociception in two acute thermal pain assays after systematic administration were evaluated in mice and compared to that of mecamylamine. Dextrometorphan and dextrorphan were found to block nicotine's antinociception in the tail-flick and hot-plate tests with different potencies (dextrometorphan is 10-times more potent than its metabolite). This blockade was not due to antagonism of NMDA receptors and/or interaction with opiate receptors, since selective drugs of these receptors failed to block nicotine's analgesic effects. Our results with the tail-flick and hotplate tests showed an interesting in vivo functional selectivity for dextrometorphan over dextrorphan. In oocytes expressing various neuronal nAChRs, dextrometorphan and dextrorphan blocked nicotine activation of expressed α 3 β 4 , α 4 β 2 and α 7 subtypes with a small degree of selectivity. However, the in vivo antagonistic potency of dextrometorphan and dextrorphan in the pain tests does not correlate well with their in vitro blockade potency at expressed nAChRs subtypes. Furthermore, the apparent in vivo selectivity of dextrometorphan over dextrorphan is not related to its in vitro potency and does suggest the involvement of other mechanisms. In that respect, dextrometorphan seems to behave as another mecamylamine, a non-competitive nicotinic receptor antagonist with a preferential activity to α 3 β 4 * neuronal nAChRs subtypes.
Dextrometorphan is structurally related to the morphinan opioid levorphanol and is widely known as a centrally acting non-narcotic antitussive agent. Although dextromethorphan produces little analgesia by itself, it was found to potentiate the antinociceptive effects of opiates and reduce tolerance and physical dependence to morphine (Mao et al., 1996) . In addition, Glick et al (2001) have shown that both dextrometorphan and its major metabolite, dextrorphan, decreased nicotine, metamphetamine and morphine self-administration in rats after s.c.
administration. These multiple pharmacological and behavioral effects may be related to the ability of dextrometorphan and dextrorphan to interact with various receptor systems.
Dextrometorphan has little or no opioid activity but binds with high affinity to σ sites (Klein and Musacchio, 1989) . It binds along with dextrorphan, with low affinity to the Phencyclidine (PCP) site of the NMDA receptor with dextrorphan having 10-fold higher affinity at the site (Franklin and Murray, 1992) . In addition, dextrometorphan and dextrorphan are both antagonists at NMDA glutamate receptors (Murray and Leid, 1984) . They were also recently shown to block α 3 β 4 neuronal nicotinic receptors in a non-competitive fashion (Hernandez et al., 2001 ) with dextrometorphan 3-fold less potent than dextrorphan.
These reports suggest that dextrometorphan and/or dextrorphan may hold promise for understanding nicotine pharmacology and nicotine dependence. However, further studies are needed to investigate the modulation of nicotine's pharmacological effects by dextrometorphan and its metabolite, and to compare their effects on various neuronal nAChRs. Although a wide range of pharmacological effects are elicited after nicotine administration, we were particularly interested in nicotine's antinociceptive action.
Activation of cholinergic pathways by nicotine elicits antinociceptive effects in a variety of species (Aceto et al., 1986; Mattila et al., 1968; Phan et al., 1973) . There is strong evidence that the antinociceptive effect of nicotine can occur via activation of nAChRs expressed in the CNS and peripheral sensory neurons (Iwamoto and Marion, 1993; Iwamoto, 1989 Iwamoto, , 1991 Bitner et al., 1998; Aceto et al., 1986; Christensen and Smith, 1990; Damaj et al., 1998; Khan et al., 1997; Flores et al., 1996) . The antinociceptive effect of nicotine is of short duration (5 -45 min) and occurs at relatively high doses (0.5 -2 mg/kg). In addition, tolerance develops after repeated administration as measured in acute thermal pain models (Damaj and Martin, 1996 (Damaj et al., 1998; Rao et al., 1996) .
In the present study, we investigated the extent to which dextrometorphan and its metabolite could alter the antinociceptive activity of nicotine in two acute thermal pain assays, the tail-flick and the hot-plate tests. The potential antagonism of nicotine-induced antinociception by dextrometorphan and dextrorphan was assessed after systemic (s.c. and i.p.
injections) administration. The route of administration of dextrometorphan can have a substantial impact on its metabolism. Much higher levels of dextrorphan are generated after an i.p. injection of dextrometorphan compared to the levels after s.c. injection (Wu et al., 1995) .
The comparison of different routes of administration will be helpful in understanding the relative extent to which dextrometorphan and dextrorphan mediates the effects of dextrometorphan on nicotine's antinociceptive activity. The effects of dextrometorphan and its metabolite were compared to that of mecamylamine, a non-competitive nicotinic antagonist with a preferential activity at α 3 β 4 receptor subtypes (Papke et al., 2001 ). In addition, the selectivity of their nicotinic response was examined by testing the effects of various dextrometorphan structural analogs, opiate-and/or NMDA receptor modulators, on nicotine-induced antinociception in mice.
In vivo studies were complemented with the in vitro profiling of dextrometorphan and dextrorphan on various neuronal nicotinic receptor subtypes. The antagonistic activity of 6 JPET # 75093 dextrometorphan and dextrorphan was assessed at the α 4 β 2 and α 3 β 4 and α 7 nicotinic receptor subtypes expressed in oocytes. (Milwaukee, WI) and converted to the ditartrate salt as described by Aceto et al. (1979) .
Dizocilpine (MK-801), dextromethorphan and dextrorphan were purchased from RBI (Natick, MA). ). Acetylcholine and other chemicals used in the oocyte buffer solutions were obtained from Sigma-Aldrich (St. Louis, MO). Naloxone, (+)-morphine, codeine isomers and levorphanol were supplied by the National Institute on Drug Abuse (Washington, DC). All drugs were dissolved in physiological saline (0.9% sodium chloride). All doses are expressed as the free base of the drug.
Antinociceptive tests.
Tail-flick test. Antinociception was assessed by the tail-flick method of D'Amour and
Smith (1941) as modified by Dewey et al. (1970) . A control response (2-4 sec) was determined for each mouse before treatment, and a test latency was determined after drug administration. In order to minimize tissue damage, a maximum latency of 10 sec was imposed. Antinociceptive response was calculated as percent maximum possible effect (% MPE), where %MPE = [(testcontrol)/(10-control)] x 100.
2. Hot-plate Test. Mice were placed into a 10 cm wide glass cylinder on a hot plate (Thermojust Apparatus) maintained at 55.0 ˚C. Two control latencies at least ten min apart were determined for each mouse. The normal latency (reaction time) was 8 to 12 seconds. jumped or licked its paws. In order to minimize tissue damage, a maximum latency of 40 sec was imposed.
Groups of eight to twelve animals were used for each dose and for each treatment.
Antagonism studies were carried out by pretreating the mice with either saline, dextrometorphan or dextrorphan 15 min before nicotine. This 15 min time was determined in separate experiments to be the optimum pretreatment time for dextrometorphan and dextrorphan (data not shown). The animals were tested 5 min after administration of nicotine. Opiate agonists and antagonists as well as NMDA antagonists were evaluated for their ability to antagonize nicotine in the tail-flick test. Codeine isomers, levorphanol (a structural analog of dextrometorphan with opiate activity) and (+)-morphine were tested at the highest inactive doses in the tail-flick test.
Naloxone (a non-selective opiate antagonist) was given at 1 mg/kg, a dose that is largely reported to block morphine's analgesic effects.
Oocytes Expression Studies.
1. Molecular Biology: The rat cDNAs for the α 3 , β 4 , α 4 and β 2 nAChRs were in pcDNAI/neo Polymerase T7, sk-Polymerase T3, psp64 Polymerase SP6 and psp65 Polymerase SP6 vectors, respectively. The human α 7 nAChR clone was in a pMXT expression vector. The vectors were linearized and used as templates for run-off transcription from the SP6 promoter using standard techniques.
2. Oocyte extraction and injection: Xenopus laevis oocytes were extracted from anesthetized females and placed in ND-96 medium (NaCl 96 mM, KCl 2 mM, MgCl 2 1 mM, CaCl 2 H 2 O 1.8 mM, HEPES 5 mM, Na-pyruvate 2.5 mM, theophylline 0.5 mM, and 10 mg/L of gentamicin, adjusted to pH 7.5). The oocyte clusters were incubated in 0.2% collagenase (type IA, Sigma-Aldrich) in ND-96 medium for defolliculation. Oocytes were agitated at 18.5°C for 4 hours and afterwards were rinsed with Barth's medium (NaCl 88 mM, KCl 1 mM, NaHCO 3 2.4 mM, HEPES 15 mM, pH 7.6). The oocytes were left to recover for 24 hr in L-15 oocyte medium before injection of cRNA. L-15 oocyte media was obtained from Specialty Media (Phillipsburg, NJ). Approximately 10 ng of cRNA was injected into individual oocytes in volumes of ~100 nl using a manual injector (Nanoject; Drummond Scientific, Broomall, PA).
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For α 4 β 2 and α 3 β 4 nicotinic receptors, cRNA for the 2 subunits was injected mixed in a 1:1 ratio. The oocytes were incubated at 17°C for 3-7 days in ND-96 medium prior to electrophysiological recording.
3. Electrophysiology: Oocytes preparation and recording was performed as previously described by Coates and Flood (2001) . Current recordings were made from whole oocytes at room temperature (19-23°C) using a Gene-Clamp 500 two-microelectrode voltage-clamp amplifier with an active ground circuit (Axon Instruments, Inc., Foster City, CA). The recording electrodes were pulled from glass capillaries (Drummond, Broomall, PA) to obtain a resistance between 1 and 5 MΩ when filled with 3M KCl. The Ringer's solution (115 mM NaCl, 2.5 mM KCl, 1.8 mM BaCl 2, 10 mM HEPES, 1 µM atropine, pH 7.4) used for recordings, contained atropine to prevent muscarinic receptor stimulation and barium in place of calcium to avoid current amplification by calcium activated chloride currents. Oocytes were clamped at a holding potential of -60mV unless otherwise indicated and held in a 125 µl cylindrical channel. All drugs were applied by perfusion at a flow rate of 4ml/min. The oocyte was pre-exposed to calculated mean and standard error were fit to a modified Hill equation. Clampex 7 (Axon Instruments, Inc., Foster City, CA) was used for data acquisition and Microcal Origin 5.0 (Microcal, Northampton, MA) was used for graphics and statistical calculation. P < 0.05 was considered significant and data were represented as mean ± SEM.
Statistical analysis. Statistical analysis of all analgesic studies was performed using either t-test or analysis of variance (ANOVA) with Tukey's test post hoc test when appropriate. All differences were considered significant at p < 0.05. AD 50 values with 95% CL for behavioral data were calculated by unweighted least-squares linear regression as described by Tallarida and Murray (1987) . (Table 1) . By themselves, dextrometorphan and dextrorphan did not significantly change tail-flick basal latencies at the indicated doses and times.

Results
Effects of dextrometorphan and dextrorphan on nicotine-induced antinociception in the tail
The potency of dextrometorphan in blocking nicotine-induced antinociception was then determined after s.c. injection. As presented in Figure 3 , dextrometorphan blocked nicotine's effects in a dose-related manner, with an AD 50 value of 0.8 (0.6-0.9) mg/kg. This value indicates that dextrometorphan given s.c. is 3-times more potent in blocking the antinociceptive effect of nicotine compared to that determined after i.p. injection [0.8 (0.6-0.9) versus 2.4 mg/kg] ( Table   1 ).
To ascertain that the dextrometorphan /nicotine in vivo interaction was specific to nicotinic systems, opiate analogs and NMDA antagonists were evaluated for their ability to 12 JPET # 75093
antagonize nicotine in the tail-flick test. As shown in Table 2 , dizocilpine (MK-801), naloxone, codeine isomers, levorphanol (a structural analog of dextrometorphan with opiate activity) and (+)-morphine given at behaviorally active doses failed to significantly block nicotine-induced antinociception in mice. Mecamylamine, given s.c. at 1 mg/kg in the same experimental conditions, totally blocked nicotine's effects in the tail-flick test.
Effects of dextrometorphan and dextrorphan on nicotine-induced antinociception in the hotplate test
In contrast to the tail-flick test, the difference in potency of dextrometorphan and dextrorphan in blocking nicotine-induced antinociception as measured by the hot-plate test was not significantly different. When given i.p. 15 min before nicotine, dextrometorphan blocked nicotine's effects in the hot-plate test in a dose-dependent manner with AD 50 of 13 (6.8-22) mg/kg. Dextrorphan blocked nicotine's effects in a dose-dependent manner with an AD 50 of 24 (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (Fig. 4) .
Effects of mecamylamine on nicotine-induced antinociception in the tail-flick and hot-plate tests
The potency of mecamylamine, a non-competitive nicotinic antagonist, in blocking nicotine's effects in the two acute thermal pain assays was compared to that of dextrometorphan and dextrorphan after s.c. treatment. Nicotine-induced antinociception after systemic administration in mice (2.5 mg/kg) in the tail-flick and hot-plate tests was blocked by mecamylamine in a dose-dependent manner (Fig. 5) . Calculation of the AD 50 showed that mecamylamine is 9-times more potent in blocking the antinociceptive effect of nicotine in the tail-flick than the hot-plate test [0.09 (0.05-0.13) versus 0.8 (0.5-1.1) mg/kg] ( Table 1) .
Interaction of dextrometorphan and dextrorphan with expressed neuronal nicotinic receptors
Since dextrometorphan and dextrorphan differentially blocked nicotine's antinociceptive effects, their potencies as blockers at various neuronal nicotinic receptors were investigated. At a concentration of 100 µM, they did not elicit any current response when applied for 60 sec to 13 JPET # 75093 oocytes expressing the α 4 β 2 , α 7 or α 3 β 4 subunit combinations (data not shown). Although they did not activate these expressed receptors, dextrometorphan and dextrorphan antagonized the effects of acetylcholine in a concentration-related manner (Fig. 6 ). In addition, dextrometorphan displayed differential potency in blocking the various nicotinic receptors with the α 3 β 4 receptor being the most sensitive. Indeed, the concentration of dextrometorphan that blocked 50% of the nicotinic current (IC 50 ) was determined to be 0.7 (0.1) and 3.9 (0.2) µM for α 3 β 4 and α 4 β 2 receptors, respectively (Table 2 ). α 7 Receptors were also sensitive to dextrometorphan blockade with an IC 50 value of 2.5 (0.2) µM ( Fig. 6 and Table 3 ). The relative selectivity seen with dextrometorphan was less evident with dextrorphan. The IC 50 values for dextrorphan were determined to be 1.3 (0.1) and 3.0 (0.5) µM for α 3 β 4 and α 4 β 2 receptors, respectively. α 7
Receptors were the least sensitive to dextrorphan blockade with an IC 50 of 4.3 (0.2) µM ( Fig. 6 and Table 3 ).
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Discussion
The primary findings of this study are that dextrometorphan and its principle metabolite dextrorphan are blockers of nicotinic antinociceptive effects and functional inhibitors of various neuronal nAChRs subtypes. These results confirm and expand the findings of previous studies that reported dextrometorphan and dextrorphan blocked α 3 β 4 expressed nicotinic receptor subtypes in HEK-293 cells (Hernandez et al., 2001 ) and decreased nicotine self-administration in rats (Glick et al., 2001 ). The higher potency in blocking α 3 β 4 subtypes expressed in oocytes found in our study compared to that reported by Hernandez et al., (2001) The present findings, together with the results of Hernandez et al., (2001) and Glick et al., (2001) , showed that dextrometorphan, widely available as an over-the-counter cough suppressant, is a nicotinic antagonist. Our results with two different routes of administration (s.c. and i.p.) as well the time-course of nicotine blockade suggest that dextrorphan, the major metabolite of dextrometorphan which possesses a comparable activity and lower toxicity to the parent compound (Fossati et al., 1995) , seems to mediate to a certain extent the effects of dextrometorphan on nicotine's analgesic actions. However, the participation of other dextrometorphan metabolites such as 3-methoxymorphinan and 3-hydroxymorphinan in its antagonistic effects cannot be excluded.
Our results with the tail-flick and hot-plate tests showed an interesting difference in in vivo functional potency for dextrometorphan and dextrorphan. First, they block nicotine's antinociception effects in the tail-flick test with different potencies (dextrometorphan is 10-times more potent that its metabolite). Second, dextrometorphan but not dextrorphan was found significantly more potent in blocking nicotine-induced antinociception in the tail-flick than the hot-plate test after systemic administration (a ratio of 5), similar to the nicotinic antagonist, mecamylamine. These observations suggest that dextrometorphan possesses some selectivity over dextrorphan for neuronal nicotinic receptors underlying these two nicotinic analgesic responses. The potency ratio in the tail-flick/hot-plate of dextrometorphan (R = 5), dextrorphan (R = 0.9) and mecamylamine (R = 12) correlates well with their in vitro α 3 β 4 /α 4 β 2 blockade potency ratio of 5.5, 2 and 4 (Papke et al., 2001) , respectively. In addition, the potency of dextrometorphan in blocking nicotine-induced antinociception in the tail-flick test after s.c.
injection increased 3-fold ( Table 1 ) compared to that obtained after i.p. administration. This difference can be explained by the fact that higher levels of dextrorphan are generated after i.p.
injection of dextrometorphan compared to the levels after s.c. injection of dextrometorphan (Wu et al., 1995) . These findings suggest that α 3 β 4 nAChRs subtypes underlie the action for dextrometorphan in blocking nicotine's effects in the tail-flick test. However, the in vivo antagonistic potency of dextrometorphan, dextrorphan and mecamylamine in the tail-flick test (see Table 1 ) does not correlate well with their in vitro blockade potency at α 3 β 4 neuronal nAChRs subtypes (Table 3) . A similar conclusion can also be reached for α 4 β 2 or α 7 nAChRs subtypes in the hot-plate test. The involvement of metabolites into dextrometorphan and dextrorphan in vivo effects may help in explaining this discrepancy. Additionally, differences 16 JPET # 75093 are likely to exist between the receptors expressed in oocytes and those found in vivo, such as additional complex subunit arrangements, post-translational modifications, etc.
The present in vitro functional findings indicate that the various neuronal nAChRs differ little in their sensitivity to inhibition by dextrometorphan and dextrorphan, which does not suggest a particular selectivity towards any of the subtypes tested. The apparent in vivo selectivity of dextrometorphan over dextrorphan is hard to explain with its in vitro potency and suggest the involvement of other mechanisms. In that respect, dextrometorphan seems to behave as another mecamylamine, a non-competitive nicotinic receptor with a preferential activity to α 3 β 4 * neuronal nAChRs subtypes.
At this point, it is difficult to predict exactly which nicotinic receptor subtypes are the most important targets for nicotinic analgesia. However, our present results along with previous reports (Bitner et al., 2000; Marubio et al., 1999) have shed some light on this question.
Contrary to our results with the hot-plate test where α 4 β 2 subtypes have major involvement, the tail-flick test data provide strong evidence that at least two mechanisms of nicotinic receptor- nicotine (2.5 mg/kg, s.c.) and mice were tested 5 min later. Each point represents the mean ± SEM of 8 to 12 mice.
Fig. 6
Concentration-dependence of dextrometorphan and dextrorphan inhibition of α 3 β 4 , α 4 β 2 and α 7 nAChRs subtypes. Responses of different neuronal nicotinic receptors to an EC 90 concentration of Ach (100 µM for α 3 β 4 , α 4 β 2 and 1000 µM for α 7 nAChRs) were recorded in the absence and presence of different concentrations of dextrometorphan and dextrorphan. Oocytes were held at60mV.
